Constructing a novel prognostic signature of tumor driver genes for breast cancer
- PMID: 35958490
- PMCID: PMC9360863
Constructing a novel prognostic signature of tumor driver genes for breast cancer
Abstract
Objectives: To systematically explore the function and prognostic ability of tumor-driver genes (TDGs) in breast carcinoma (BRCA).
Methods: Functional enrichment analysis of BRCA differentially expressed TDGs was assesed. We used univariate Cox, lasso, and multivariate Cox regression to identify the independent prognostic TDGs of BRCA. Then we constructed a prognostic signature and verified its predictive performance. Gene set enrichment analysis of the signal pathway revealed the differences between the prognostic signature high- and low-risk groups. Finally, a nomogram related to the prognostic model was established and verified.
Results: A total of 595 differentially expressed TDGs were identified, which are related to various molecular mechanisms of BRCA progression. We identified 8 independent prognostic TDGs for BRCA and validated their expression and prognosis with public data and clinical samples. The BRCA cohort was divided into training and validation cohorts, and prognostic signatures were constructed separately. The log-rank test showed that the survival rate of the high-risk group was significantly lower than that of the low-risk group in the prognostic signature (P<0.001); the AUC in the three cohorts were 0.805, 0.712, and 0.760, respectively; the nomogram also showed better predictive performance. Analyzing the difference between the two risk subtypes, the high-risk group is mainly enriched in angiogenesis, MTORC1, epithelial-mesenchymal transition and glycolysis, which means it is highly malignant.
Conclusions: The prognostic signature and nomogram was confirmed to accurately predict the prognosis of patients with BRCA and we validated the hub genes, suggesting their potential as future therapeutic targets.
Keywords: Breast cancer; nomogram; prognostic signature; tumor drive gene.
AJTR Copyright © 2022.
Conflict of interest statement
None.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9360863/bin/ajtr0014-4515-f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9360863/bin/ajtr0014-4515-f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9360863/bin/ajtr0014-4515-f3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9360863/bin/ajtr0014-4515-f4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9360863/bin/ajtr0014-4515-f5.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9360863/bin/ajtr0014-4515-f6.gif)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9360863/bin/ajtr0014-4515-f7.gif)
Similar articles
-
Identification and validation of a novel prognostic signature based on transcription factors in breast cancer by bioinformatics analysis.Gland Surg. 2022 May;11(5):892-912. doi: 10.21037/gs-22-267. Gland Surg. 2022. PMID: 35694087 Free PMC article.
-
Identification of a pyroptosis-related prognostic signature in breast cancer.BMC Cancer. 2022 Apr 20;22(1):429. doi: 10.1186/s12885-022-09526-z. BMC Cancer. 2022. PMID: 35443644 Free PMC article.
-
A Novel Signature Integrated of Immunoglobulin, Glycosylation and Anti-Viral Genes to Predict Prognosis for Breast Cancer.Front Genet. 2022 Apr 1;13:834731. doi: 10.3389/fgene.2022.834731. eCollection 2022. Front Genet. 2022. PMID: 35432482 Free PMC article.
-
Detecting prognostic biomarkers of breast cancer by regularized Cox proportional hazards models.J Transl Med. 2021 Dec 20;19(1):514. doi: 10.1186/s12967-021-03180-y. J Transl Med. 2021. PMID: 34930307 Free PMC article.
-
Identification of a Twelve-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival for Medulloblastoma.Front Genet. 2020 Sep 3;11:563882. doi: 10.3389/fgene.2020.563882. eCollection 2020. Front Genet. 2020. PMID: 33101383 Free PMC article.
References
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. - PubMed
-
- Pernas S, Barroso-Sousa R, Tolaney SM. Optimal treatment of early stage HER2-positive breast cancer. Cancer. 2018;124:4455–4466. - PubMed
-
- Koshiba M. Molecular targeted therapy and laboratory tests. Rinsho Byori. 2016;64:709–716. - PubMed
-
- Weber BL. Cancer genomics. Cancer Cell. 2002;1:37–47. - PubMed
LinkOut - more resources
Full Text Sources